Table 3. Outcomes of patients with chronic obstructive pulmonary disease and acute myocardial infarction.
| Weighted incidence rate (per 100 person-years) | Adjusted weighted rate ratio | ||||
|---|---|---|---|---|---|
| β-blockers | NDCCB | Control | β-blockers vs. Control | β-blockers vs. NDCCB | |
| 1-year mortality | 9.2 | 9.9 | 11.6 | 0.81 (0.74–0.88)*** | 0.90 (0.77–1.07) |
| Overall mortality | 8.0 | 8.6 | 9.2 | 0.88 (0.84–0.93)*** | 0.91 (0.83–0.99)* |
| MACE in 1 year | 45.7 | 44.7 | 46.4 | 0.98 (0.94–1.03) | 1.01 (0.93–1.10) |
| Repeated MI | 10.4 | 9.6 | 8.7 | 1.08 (0.99, 1.18) | 1.17 (0.98, 1.40) |
| Repeated revascularization | 28.1 | 26.0 | 26.6 | 1.04 (0.98, 1.10) | 1.05 (0.95, 1.17) |
| Ischemic stroke | 3.7 | 3.7 | 3.8 | 0.98 (0.85, 1.13) | 0.97 (0.74, 1.26) |
| Acute medical services use in 1 year† | |||||
| Obstructive lung disease | 27.9 | 39.9 | 36.6 | 0.74 (0.69–0.80)*** | 0.68 (0.60–0.78)*** |
| Respiratory diseases | 68.1 | 77.1 | 76.6 | 0.88 (0.84–0.93)*** | 0.88 (0.80–0.97)* |
*p <0.05,
**p <0.01,
***p <0.001.
† Incidence rate per 10 person-years
Patients were classified into the β-blockers, the non-dihydropyridine calcium channel blocker (NDCCB), and the control groups according to the outpatient prescription within 2 weeks after hospital discharge.
Abbreviations: MACE, major adverse cardiac events;